We seek for new chemical compounds and deliver to the world.
Chemiteras is a fine chemical company contributing to the health and longevity.
| Chemiteras,Inc. | |
|---|---|
| Company name | Chemiteras,Inc. |
| Head Office | 3-chome-24-5 Shinnyokohama,Kohoku Ward, Yokohama, Kanagawa, 222-0033, Japan |
| company representative | Tokinori Terada |
| foundation | 2017.9.13 |
| Business | R&D of chemical compounds. Machinery development. Utilization of intellectual properties. Planning, manufacturing, sales of health food. |
| E-mail address | info@chemiteras.com |
| E-mail address | info@chemiteras.com |
| Jun.2022 | Chemiteras has signed an agreement for exclusive sales right in Japan with Safely2Prosperity LLC (Headquarters: Massachusetts, USA, Representative Director: John Norris), a leading company that provides cloud-based software as a corporate and organizational management system for next-generation infectious diseases. ■ Chemiteras Inc. and Safely2Prosperity LLC Signed an Agreement for Exclusive Sales Right in Japan（Japanese only） Additionally, John Norris, the founder＆CEO of Safely2Prosperity, has been appointed as one of our advisors. |
|---|---|
| Jan.2022 |
SIRTUP, a dietary supplement containing deazaflavine, a seed compound for drug discovery based on our patented technology, has been released by Life Science Lab Co. ■SIRTUP Product Overview（Japanese only） |
| Oct.2021 | Release: News release published in multiple media including PRTIMES ■「Successful development and patent acquisition of a compound showing mitochondrial activity」（Japanese only） |
| Sep.2021 | “UNIPLAT” was officially launched on September 28, 2021. ■UNIPLAT（https://www.uniplat.social） |
| Nov.2020 | The online support platform for researchers "UNIPLAT", which we are entrusted with system development, has been published in the Group of Nations, a public relations magazine of the international summits. ■Group of Nations / G20 GLOBAL BRIEFING REPORT 2020 (UNIPLAT is on pages 156 and 157) This magazine is an official publication for international conferences such as G8, G20, APEC. |
| Aug.2019 | Signed an advisory agreement with Dr. Torkel Falkenberg, deputy head for Karolinska Institutet Center for Social Sustainability in Sweden. |
| Mar.2019 | Joint development： Patent applications of a seed compound for the brain cancer drug |
| Feb.2019 | In-house development： Patent application of a seed compound for the mitochondrial related drug |
| Aug.2018 | In-house development： Patent applications of a seed compound for the Hyperuricemia treatment drug |
| Jun.2022 | Chemiteras has signed an agreement for exclusive sales right in Japan with Safely2Prosperity LLC (Headquarters: Massachusetts, USA, Representative Director: John Norris), a leading company that provides cloud-based software as a corporate and organizational management system for next-generation infectious diseases. ■ Chemiteras Inc. and Safely2Prosperity LLC Signed an Agreement for Exclusive Sales Right in Japan（Japanese only） Additionally, John Norris, the founder＆CEO of Safely2Prosperity, has been appointed as one of our advisors. |
